Shalby Ltd

Shalby Management Change

Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.

Shalby Annual General Meeting

Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.

Shalby Other Announcement

Shalby Limited has issued a letter to shareholders providing the web-link for the Annual Report for FY 2025-26. The 22nd Annual General Meeting is scheduled for September 10, 2026.

Shalby Business Update

Shalby Limited filed its Business Responsibility & Sustainability Report (BRSR) for FY 2025-26 as mandated by SEBI LODR regulations.

Shalby Annual General Meeting

Shalby Ltd announced its 22nd Annual General Meeting scheduled for September 10, 2026, and filed its Annual Report for FY 2025-26.

Shalby Earnings Call Transcript: Key Takeaways

Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.

Call

Guides 20% growth

Shalby Investor Presentation: Key Takeaways

Shalby Limited reported Q1 FY27 consolidated revenue of ₹3,386 mn, up 11.6% YoY, and PAT of ₹105 mn, up 36.7% YoY. Focus remains on orthopedic leadership and expanding implant business.

Shalby Board Meeting Outcome

Shalby Limited appointed Mr. Shanay Vikram Shah as an Additional Director designated as Whole-Time Director, effective August 12, 2026. This follows today's board meeting.

Shalby Employee Stock Options

Shalby Limited granted 15,000 employee stock options to eligible employees under its 2021 ESOP scheme, with an exercise price of ₹100 per option.

Shalby Management Change

Shalby Limited appointed Mr. Shanay Vikram Shah as an Additional Director designated as Whole-Time Director for a five-year term, effective August 12, 2026. He is also designated as a Key Managerial Personnel.

Shalby Q1 FY27 Results: Net Profit ₹10.5 Cr, Up 36.4% YoY

Shalby Ltd reported revenue from operations of ₹331.2 Cr (+11.7% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for Q1 FY27.

Key figure

Net profit ₹10.5 Cr · +36.4% YoY

Shalby Employee Stock Options

Shalby Limited reported the exercise of 3,000 employee stock options on August 10, 2026. The exercise occurred via the Employee Welfare Trust, impacting no paid-up capital.

Value

₹0.03 Cr

Shalby Debt & Borrowing: ₹129.7 Cr

Shalby Limited approved availing working capital facilities totaling ₹129.70 crore from Kotak Mahindra Bank Limited. This includes funding for both the company and its US subsidiary.

Value

₹129.7 Cr

Shalby Board Meeting Date

Shalby Limited has rescheduled its board meeting from August 5, 2026, to August 12, 2026, due to unavoidable exigencies.

Shalby Credit Rating

ICRA Limited downgraded Shalby Limited's credit rating to [ICRA]A from [ICRA]A+, while revising the outlook from Negative to Stable for ₹830 Crore of credit facilities.

Value

₹830.0 Cr

Shalby Employee Stock Options

Shalby Limited announced the exercise of 6,000 stock options by eligible employees under its ESOP scheme, with shares transferred from the Employee Welfare Trust.

Shalby Board Meeting Date

Shalby Limited will hold a board meeting on August 5, 2026. The board will consider and approve unaudited financial results for the June 2026 quarter.

Shalby Employee Stock Options

Shalby Limited announced the exercise of 20,500 employee stock options. The exercise realized ₹0.21 Crore, with shares transferred from the employee welfare trust.

Value

₹0.20 Cr

Shalby Legal & Regulatory

Shalby Limited announced the settlement of arbitration proceedings with Dr. Viral Shah and Dr. Praveen Saxena. The disputes were disposed of with no financial impact.

Shalby Results Correction

Shalby Limited clarified an inadvertent EPS error in its XBRL financial results. The company corrected the labels for continued and discontinued operations.

Shalby Earnings Call: Key Takeaways

Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.

Shalby Earnings Call: Key Takeaways

Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.

Shalby Other Announcement

Shalby Limited corrected a typographical error regarding its Cost Auditor firm appointment for FY 2026-27. S A & Associates replaces the previously mentioned firm.

Execution

FY 2026-27

Shalby Earnings Call: Key Takeaways

Shalby Limited reports Q4 FY26 consolidated revenue growth of 9.4% YoY. The company is scaling its MedTech implant business and expanding hospital capacity through an asset-light O&M model.

Shalby Earnings Call: Key Takeaways

Shalby Limited delivered Q4 FY26 consolidated revenue growth of 9.4% YoY. Strategy focuses on diversifying specialties beyond arthroplasty and expanding the MedTech implant business.

Shalby Employee Stock Options

Shalby Limited granted 4,000 ESOPs at an exercise price of ₹100 per option. This long-term incentive plan aligns employee interests with shareholder value creation.

Value

₹0.04 Cr

Execution

2 year vesting; 1 year exercise

Shalby Q4 FY26 Results: Turns Profitable, Net Profit ₹18.5 Cr

Shalby Ltd reported revenue from operations of ₹287.4 Cr (+8.5% YoY) and net profit of ₹18.5 Cr for Q4 FY26.

Key figure

Net profit ₹18.5 Cr

Shalby Financial Results

Shalby Ltd reported audited FY2026 standalone revenue of ₹8,985.58 Million. The board did not recommend a dividend and appointed new cost auditors for FY2027.

Shalby Merger & Restructuring

Shalby Limited's step-down subsidiary, Ningen Lifecare, has been struck-off by the MCA. The non-operational entity's closure has no material financial impact on company operations.

Shalby Board Meeting Date

Shalby Ltd scheduled a board meeting on May 27, 2026, to approve audited financial results and recommend a dividend. The trading window remains closed.